Last updated: April 25, 2026
JARDIANCE: Who Supplies It and What’s Under the Hood of the Supply Chain
JARDIANCE is the brand name for empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. The commercial product is supplied through a defined global manufacturing network with multiple drug-substance (API) and finished-dose (FDF) sites, typically under contractual arrangements with Boehringer Ingelheim (brand owner) and its approved manufacturing partners.
Who is the primary supplier of JARDIANCE (brand owner and global manufacturing responsibility)?
Boehringer Ingelheim is the marketing authorization holder / brand owner for JARDIANCE in major markets and holds responsibility for global product supply and quality systems for empagliflozin drug product.
Key operational implication: Contract manufacturing and packaging can vary by market and by year, but the product is still governed by Boehringer Ingelheim quality and regulatory frameworks.
Which companies supply the drug substance (empagliflozin API) used to make JARDIANCE?
Empagliflozin API supply is handled by approved API manufacturers across different geographies. In practice, Boehringer Ingelheim uses multiple sources to maintain continuity and batch supply.
Because API sourcing is controlled via approved vendor qualification and often changes at the site and batch level, the most defensible “supplier list” is the one embedded in regulatory product dossiers and US FDA Orange Book manufacturing/distribution records for labeled strengths.
What are the identified finished-dose (tablet) manufacturing suppliers for JARDIANCE?
JARDIANCE tablets are produced through Boehringer Ingelheim’s approved manufacturing and packaging network. Finished-dose supply is also batch- and market-dependent (strength and packaging configuration), so the “supplier” view is best anchored to labelled manufacturers and regulatory listings that name specific sites.
What does the label-level supplier evidence look like in the US market?
For the US, “supplier” is best treated as the labeled manufacturer/packager listed on FDA/label documents for each dosage form and strength. The Orange Book and prescribing information identify listed manufacturers and label holders for empagliflozin product configurations.
JARDIANCE Supply: Concrete supplier mapping approach
Use this structured mapping for investment-quality supplier due diligence:
- Regulatory holder: Boehringer Ingelheim (JARDIANCE brand responsibility).
- US labelled manufacturing sites: manufacturers/packagers listed on the US prescribing information and FDA Orange Book records for each tablet strength.
- API sourcing: manufacturers listed in the drug substance sections of regulatory dossiers and referenced through inspection histories and publicly listed approvals.
This approach avoids speculative third-party “supplier” claims that do not map to labeled or approved sites.
Key Takeaways
- Boehringer Ingelheim is the brand owner and supplier-of-record for JARDIANCE product quality and regulatory compliance globally.
- Tablet manufacturing and packaging suppliers vary by strength and market and are best confirmed through the US label/Orange Book and local regulatory listings that name specific sites.
- API sourcing uses multiple approved manufacturers; robust identification requires regulatory dossier site names rather than informal vendor lists.
FAQs
-
Is JARDIANCE supplied by a single manufacturer worldwide?
No. Finished-dose and packaging sites vary by strength and geography; quality oversight remains with Boehringer Ingelheim.
-
Who makes empagliflozin (the drug substance) for JARDIANCE?
Multiple approved API manufacturers supply empagliflozin to Boehringer Ingelheim. The authoritative supplier set is the one named in regulatory and label-related records.
-
Where can I confirm the tablet manufacturer for JARDIANCE in the US?
The US prescribing information and FDA Orange Book listings for the relevant strength show the labeled manufacturer and associated manufacturing/packaging information.
-
Do API and finished-dose suppliers have to be the same company?
No. API suppliers and finished-dose manufacturers are often different entities operating under qualification and supply agreements.
-
Does the supplier list change over time?
Yes. Approved manufacturing sites can be added, substituted, or geographically rebalanced based on capacity, approvals, and compliance outcomes.
References (APA)
[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] U.S. Food and Drug Administration. (n.d.). Drug label information for empagliflozin (JARDIANCE). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[3] Boehringer Ingelheim. (n.d.). JARDIANCE product information and prescribing information resources. https://www.boehringer-ingelheim.com
